|
Breast Cancer Drugs: World Market Prospects 2010-2025
|
|||||||||||
| Features of this market research: |
This report gives you the following benefits in particular: 135 seiten | |||||||||||
| About this market survey: |
The breast cancer treatments market generated pharmaceutical revenues of over $11bn worldwide in 2009. The incidence and prevalence of breast cancer have been rising worldwide, in line with ageing pop.....
The breast cancer treatments market generated pharmaceutical revenues of over $11bn worldwide in 2009. The incidence and prevalence of breast cancer have been rising worldwide, in line with ageing populations, lifestyle/environmental factors and improvements in diagnosis. Expanding patient populations worldwide offer significant commercial and therapeutic opportunities, which our new report forecasts and discusses. Governments and other healthcare providers are investing in health education, diagnosis and treatments for this serious - but controllable - disorder. As Breast Cancer Drugs: World Market Prospects 2010-2025 shows, breast cancer treatment is prominent in the healthcare sector. Which segments of the breast cancer market will grow fastest in years to come? How will the industry cope with patent expiry? What are the therapeutic and commercial trends to watch? How will national markets perform from 2010 to 2025? What will happen to the current leading products and drug classes? Our new report covers those and other questions, providing the information that you need. We predict that the global market for breast cancer drugs will expand from 2010 onwards, driven by significant prevalence of the disease in developed and developing countries. National markets for those products will expand at different rates, as will different treatment forms. The market will depend upon newer, more-effective products for its success. Our report shows how technologies that increase clinical effectiveness, safety and ease of use will be crucial therapeutically and commercially, benefiting healthcare stakeholders in breast cancer treatment. Detailed analysis of the breast cancer disorders industry and market Breast Cancer Drugs: World Market Prospects 2010-2025 examines that sector through a comprehensive review of information sources. We harness both primary and secondary research. This report provides unique sales forecasts, market share analyses, discussions of the R&D pipeline and analyses of commercial drivers and restraints, including a SWOT analysis. There are over 40 tables and 30 figures included, as well as three full interviews with experts. The result is a comprehensive market- and industry-centred study, with detailed analyses and informed opinion to benefit your work. Report Highlights Companies Listed Abbott Laboratories Abraxis Bioscience Inc. ADVENTRX Pharmaceuticals Agence Nationale de Valorisation de la Recherche (ANVAR) American Civil Liberties Union (ACLU) American Society of Clinical Oncology Amgen Apotex Apthera ASTA Medica Oncology AstraZeneca Baxter International Bayer Boehringer Ingelheim Bristol-Myers Squibb British Medical Journal Cancer Research UK Centre National de la Recherche Scientifique (CNRS) Cephalon Chugai Pharmaceutical Co. Consortium on Breast Cancer Pharmacogenomics (COBRA) CytImmune Sciences Eisai Eli Lilly Endocyte European Medicines Agency (EMEA) Florida State University Food and Drug Administration (FDA) Genentech GlaxoSmithKline GTx Hologic Hospira ICI Pharmaceuticals Indiana University School of Medicine International Monetary Fund (IMF) Ipsen Johnson & Johnson Journal of Medical Screening KuDOS Pharmaceuticals Kyowa Hakko Kirin Laboratoires Pierre Fabre mAbs Medicare Merck & Co. Merck KGaA Merck Serono Myriad Genetics National Cancer Institute (NCI, US) National Health Service (NHS, UK) National Institute for Clinical Excellence (NICE, UK) Novartis Oncothyreon Orion Corporation Pfizer Piramed Prima BioMed Regeneron Roche sanofi-aventis Serono STADA Arzneimittel AG Teva Pharmaceutical Industries The Mayo Clinic Tufts University US Preventative Services Task Force World Bank World Health Organisation (WHO) Wyeth (now part of Pfizer) [Fade out the market survey infos] |
|||||||||||
|
1. Executive Summary 1.1 Breast Cancer Market Review 1.2 Aims, Scope and Format of the Report 1.3 Chapter Outline 1.4 Research & Analysis Methods 2. Introduction to Breast Cancer 2.1 What is Breast Cancer? 2.2 Types of Breast Cancer 2.2.1 Pathology 2.2.2 Tumour Grade 2.2.3 Tumour Markers 2.2.4 The Staging System 2.3 Symptoms and Diagnosis 2.4 Risk Factors for Breast Cancer 2.5 Epidemiology of Breast Cancer 2.5.1 How Common is Breast Cancer? 2.5.2 How Does Geography Affect Breast Cancer Rates? 2.5.3 Is Incidence Rising? 3. Treatments for Breast Cancer, 2010 3.1 Chemotherapies 3.1.1 Anthracyclines 3.1.2 Drugs that Interfere with Microtubules 3.1.3 Anti-metabolites 3.1.4 Alkylating Agents (Cross-linkers) 3.1.5 Common Chemotherapy Combinations 3.2 Hormone Therapies 3.3 Targeted Therapies 3.4 Treatment Protocol 4. The Global Breast Cancer Market, 2009-2025 4.1 The Global Oncology Market 4.2 The Oncology Market by Therapy Type 4.3 The Breast Cancer Market 4.4 Global Breast Cancer Market Forecast 4.5 Targeted Therapy Submarket Forecast 4.6 Hormone Therapy Submarket Forecast 4.7 Cytotoxic Chemotherapies Submarket Forecast 5. Leading Breast Cancer Drugs – Global Market Prospects from 2010 5.1 Herceptin (trastuzumab, Roche) 5.1.1 Forecast and Analysis 5.2 Tykerb/Tyverb (lapatinib, GlaxoSmithKline) 5.2.1 Forecast and Analysis 5.3 Avastin (bevacizumab, Roche) 5.3.1 Forecast and Analysis 5.4 Nolvadex (tamoxifen, AstraZeneca) 5.4.1 Forecast and Analysis 5.5 Faslodex (fulvestrant, AstraZeneca) 5.5.1 Forecast and Analysis 5.6 Fareston (toremifene, Orion, GTx) 5.6.1 Forecast and Analysis 5.7 Arimidex (anastrazole, AstraZeneca) 5.7.1 Forecast and Analysis 5.8 Femara (letrozole, Novartis) 5.8.1 Forecast and Analysis 5.9 Aromasin (exemestane, Pfizer) 5.9.1 Forecast and Analysis 5.10 Zoladex (goserelin, AstraZeneca) 5.10.1 Forecast and Analysis 5.11 Taxol (paclitaxel, Bristol-Myers Squibb) 5.11.1 Forecast and Analysis 5.12 Abraxane (paclitaxel, Abraxis) 5.12.1 Forecast and Analysis 5.13 Taxotere (docetaxel, sanofi-aventis) 5.13.1 Forecast and Analysis 5.14 Ixempra (ixabipilone, Bristol-Myers Squibb) 5.14.1 Forecast and Analysis 5.15 Navelbine (vinorelbine, Pierre Fabre, GlaxoSmithKline, Baxter International) 5.15.1 Forecast and Analysis 5.16 Xeloda (capecitabine, Roche) 5.16.1 Forecast and Analysis 5.17 Gemzar (gemcitabine, Eli Lilly) 5.17.1 Forecast and Analysis 6. Prominent Companies in the Breast Cancer Sector 6.1 AstraZeneca 6.2 Roche 6.3 Bristol-Myers Squibb 6.4 Sanofi-Aventis 6.5 Abraxis BioScience 6.6 Hologic Inc. 6.7 Myriad Genetics 7. Prominent R&D Pipeline Agents in the Breast Cancer Sector, 2010 7.1 PARP Inhibitors 7.2 HER2/erbB 7.2.1 I-SPY2 TRIAL 7.3 Angiogenesis 7.4 Apoptosis 7.5 EGFR 7.6 Microtubules 7.7 Other Tyrosine Kinase 7.8 MUC-1 8. Geographical Breakdown of the Breast Cancer Market, 2010-2025 8.1 Leading National Breast Cancer Markets in 2009 8.2 Leading National Market Forecasts, 2010-2025 8.3 The US: Breast Cancer Drug Market 8.4 Japan: Breast Cancer Drug Market 8.5 Europe: Breast Cancer Drug Markets 8.6 China: Breast Cancer Drug Market 8.7 India: Breast Cancer Drug Market 9. Factors Affecting the Breast Cancer Drug Market, 2010-2025 9.1 Drivers of the Market 9.1.1 High Profile of the Disease 9.1.2 Number of Cases: Screening, Westernisation of Developing Nations, Growing Populations 9.1.3 The Price of Drugs 9.1.4 Drug Development 9.1.5 Live Licensing 9.1.6 The Cost of Non-Pharmacological Treatments 9.1.7 Treatment v Cure 9.1.8 Better Understanding of Breast Cancer Physiology 9.1.9 Personalised Medicine 9.1.10 Drug Delivery Systems 9.2 Restraints 9.2.1 The Cost-Effectiveness Debate 9.2.2 Healthcare Budgets 9.2.3 Efficacy, Toxicity and Alternative Treatments 9.2.4 The Patent Cliff 9.3 Unmet Needs in Treatment of Breast Cancer 9.3.1 Tolerable Drugs 9.3.2 More-Convenient Drugs 9.3.3 Tumour Resistance Must be Overcome 9.3.4 Greater Use of Pharmacogenomics 9.3.5 Rigorous Endpoints in Clinical Trials 9.3.6 The Screening Debate 9.3.7 Access to Novel Therapies in the Developing World 10. Interviews with Experts 10.1 David A. Flockhart, PhD, MD 10.1.1 The Importance of Pharmacogenomics in Treating Breast Cancer 10.1.2 Major Breakthroughs 10.1.3 Personalised Medicine 10.1.4 Drivers 10.1.5 Restraints 10.1.6 Ethical Issues 10.1.7 Pre-emptive Treatment 10.2 Janice M. Reichert, PhD 10.2.1 Challenges and Opportunities for Monoclonal Antibody Cancer Therapeutics 10.2.2 Future Developments and Pipelines 10.2.3 The Effect of Biosimilars 10.3 David Blakey, PhD 10.3.1 The Future of Humanised and Fully-Human Antibodies 10.3.2 Therapeutic Antibody Fragments Versus Full-Length IgGs 10.3.3 Leading Opportunities in Monoclonal Antibody Cancer Therapeutics 11. Conclusions 11.1 The Breast Cancer Market is Strong and Expected to Grow from 2010 11.2 Leading Treatments for Breast Cancer 11.3 Will the R&D Pipeline Offset the Effects of Patent Expiry? 11.4 The US is the Most Important Breast Cancer Market, but China’s Growth is Faster 11.5 Personalised Medicine is the Future of Breast Cancer Treatment? 11.6 Unmet Needs in the Breast Cancer Market 11.7 Concluding Remarks [Fade out table of contents] |
||||||||||||
|
Table 2.1 Types of Breast Cancer Table 2.2 Bloom-Richardson Grading System Table 2.3 TNM Staging System for Breast Cancer Table 2.4 Cancers by Incidence, 2009 Table 2.5 Female Cancers by Incidence, 2009 Table 2.6 Female Cancers by Mortality, 2009 Table 2.7 Age-Standardised Mortality and Incidence of Breast Cancer in Developed and Developing Countries, 2002 Table 2.8 Survival Rates for Selected Cancers, 2010 Table 2.9 US Breast Cancer Incidence Rates, 1975-2006 Table 2.10 Breast Cancer Incidence Rates in Nordic Countries, 1998-2005 Table 3.1 Chemotherapy Combinations for Breast Cancer Table 4.1 Global Pharmaceutical Sales by Disease Area, 2009 Table 4.2 Oncology Market by Therapy Type, 2009 Table 4.3 Breast Cancer Market by Therapy Type, 2009 Table 4.4 Breast Cancer Market Forecast: Overall and by Therapy Type, 2010-2025 Table 5.1 Herceptin Sales Forecast, 2010-2025 Table 5.2 Tykerb Sales Forecast, 2010-2025 Table 5.3 Avastin Sales Forecast, 2010-2025 Table 5.4 Nolvadex Sales Forecast, 2010-2025 Table 5.5 Faslodex Sales Forecast, 2010-2025 Table 5.6 Fareston Sales Forecast, 2010-2025 Table 5.7 Arimidex Sales Forecast, 2010-2025 Table 5.8 Femara Sales Forecast, 2010-2025 Table 5.9 Aromasin Sales Forecast, 2010-2025 Table 5.10 Zoladex Sales Forecast, 2010-2025 Table 5.11 Taxol Sales Forecast, 2010-2025 Table 5.12 Abraxane Sales Forecast, 2010-2025 Table 5.13 Taxotere Sales Forecast, 2010-2025 Table 5.14 Ixempra Sales Forecast, 2010-2025 Table 5.15 Navelbine Sales Forecast, 2010-2025 Table 5.16 Xeloda Sales Forecast, 2010-2025 Table 5.17 Gemzar Sales Forecast, 2010-2025 Table 5.18 Leading Breast Cancer Drugs: Sales Forecasts, 2010-2025 Table 6.1 AstraZeneca Breast Cancer Portfolio, 2009 Table 6.2 Roche Breast Cancer Portfolio, 2009 Table 6.3 Bristol-Myers Squibb Breast Cancer Portfolio, 2009 Table 6.4 Sanofi-Aventis Breast Cancer Portfolio, 2009 Table 6.5 Abraxane Breast Cancer Portfolio, 2009 Table 7.1 Promising Pipeline Agents for Breast Cancer, 2010 Table 8.1 Leading National Breast Cancer Markets: Sales and Market Shares, 2009 Table 8.2 Leading National Breast Cancer Markets: Sales Forecasts, 2010-2025 Table 8.3 US Breast Cancer Incidence, 2001-2006 Table 8.4 Breast Cancer Incidence by Country, 2002 Table 8.5 Healthcare Spending in Europe, 2009 Table 9.1 SWOT Analysis of the Breast Cancer Drug Market, 2010-2025 Table 9.2 GDP Forecasts for BRICT Countries and US, 2010-2025 Figure 2.1 Top Ten Cancers by Incidence, 2009 Figure 2.2 Top Ten Female Cancers by Incidence, 2009 Figure 2.3 Top Ten Female Cancers by Mortality, 2009 Figure 2.4 Age-Standardised Mortality and Incidence of Breast Cancer in Developed and Developing Countries, 2002 Figure 2.5 Survival Rates for Selected Cancers, 2010 Figure 2.6 US Breast Cancer Incidence Rates, 1975-2006 Figure 2.7 Breast Cancer Incidence Rates in Nordic Countries, 1975-2006 Figure 4.1 Oncology Market by Therapy Type, 2009 Figure 4.2 Breast Cancer Market by Therapy Type, 2009 Figure 4.3 Global Breast Cancer Market Sales Forecast, 2010-2025 Figure 4.4 Breast Cancer Targeted Therapies Submarket Sales Forecast, 2010-2025 Figure 4.5 Breast Cancer Hormone Therapies Submarket Sales Forecast, 2010-2025 Figure 4.6 Breast Cancer Chemotherapy Submarket Sales Forecast, 2010-2025 Figure 4.7 Global Breast Cancer Market: Sales Forecast by Therapy Type, 2010-2025 Figure 5.1 Herceptin Sales Forecast, 2010-2025 Figure 5.2 Tykerb Sales Forecast, 2010-2025 Figure 5.3 Avastin Sales Forecast, 2010-2025 Figure 5.4 Nolvadex Sales Forecast, 2010-2025 Figure 5.5 Faslodex Sales Forecast, 2010-2025 Figure 5.6 Fareston Sales Forecast, 2010-2025 Figure 5.7 Arimidex Sales Forecast, 2010-2025 Figure 5.8 Femara Sales Forecast, 2010-2025 Figure 5.9 Aromasin Sales Forecast, 2010-2025 Figure 5.10 Zoladex Sales Forecast, 2010-2025 Figure 5.11 Taxol Sales Forecast, 2010-2025 Figure 5.12 Abraxane Sales Forecast, 2010-2025 Figure 5.13 Taxotere Sales Forecast, 2010-2025 Figure 5.14 Ixempra Sales Forecast, 2010-2025 Figure 5.15 Navelbine Sales Forecast, 2010-2025 Figure 5.16 Xeloda Sales Forecast, 2010-2025 Figure 5.17 Gemzar Sales Forecast, 2010-2025 Figure 8.1 Leading National Breast Cancer Markets (Upper Tier): Sales Forecasts, 2010-2025 Figure 8.2 Leading National Breast Cancer Markets (Lower Tier): Sales Forecasts, 2010-2025 [Fade out list of tables / figures] |
||||||||||||
| Price ** (Report format): |
free of shipping costs ** IMPORTANT: All prices are net prices without taxes. Depending on the country in your billing address you have to pay sales taxes. If you have given us your billing adress, VAT No., etc. the correct total amount will be stated in the following order process. More informations on prices and taxes please find in our FAQs. |
|||||||||||
| Notice for this market research report: | * The invoice amount for this study is accounted in $ (dollar). Your bank or your credit card supplier will calculate the topical day course in your currency to you on payment. | |||||||||||
